Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23612278 | 0.83 | KMT2A (0.38) | ALDH1A1HSD17B10KMT2AMEN1MAPT | |
| SCHEMBL3942261 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HSD17B10KMT2AMEN1TDP1 | |
| SCHEMBL29438693 | 0.80 | ALDH1A1 (0.54) | ALDH1A1HSD17B10KMT2AMEN1MAPT | |
| SCHEMBL364459 | 0.80 | ALDH1A1 (0.54) | ALDH1A1HSD17B10KMT2AMEN1MAPT | |
| SCHEMBL29606539 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HSD17B10KMT2AMEN1TDP1 | |
| SCHEMBL3934740 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HSD17B10KMT2AMEN1MAPT | |
| Ammonia Solution, Strong SCHEMBL27652614 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1TDP1TSHR | |
| SCHEMBL10857430 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HSD17B10KMT2AMEN1MAPT | |
| SCHEMBL15529688 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HSD17B10KMT2AMEN1MAPT | |
| SCHEMBL19427155 | 0.77 | ALDH1A1 (0.45) | ALDH1A1KMT2AMEN1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4673436-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NEXYS THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | NEXYS THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| WO-2024179948-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-09-06 | — | — | WO | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| CN-102958918-A | Novel nicotinamide derivatives or salts thereof | FUJIFILM CORP | 2013-03-06 | — | — | CN | disclosed |
| WO-2012002577-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | 富士フイルム株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
| US-20070179295-A1 | Triazolopyrimidines | BAYER CROPSCIENCE AG (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179295-A1 | Triazolopyrimidines | BAYER CROPSCIENCE AG (DE) | 2007-08-02 | — | — | US | disclosed |
| EP-0473267-B1 | Acylaminopyridinecarboxamides, process for their preparation and their use as fungicides | ZENECA LTD (GB) | 1997-10-01 | — | — | EP | disclosed |
| US-5334722-A | For plants | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-08-02 | — | — | US | disclosed |
| EP-0473267-A2 | Acylaminopyridinecarboxamides, process for their preparation and their use as fungicides | ZENECA LIMITED (GB) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | TGFBR1, TGFBR2, ACVR1 | ALDH1A1 419/4885HSD17B10 3128/4885KMT2A 1557/4885 |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | ALDH1A1 1638/4885HSD17B10 2178/4885KMT2A 1162/4885 |
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | PKN3, PKMYT1, IP6K3 | ALDH1A1 3032/4885HSD17B10 1650/4885KMT2A 557/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885HSD17B10 1470/4885KMT2A 1951/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885HSD17B10 1470/4885KMT2A 1951/4885 |
| US-20070179295-A1 | Triazolopyrimidines | QDPR, DPYD, CYP1B1 | ALDH1A1 431/4885HSD17B10 3521/4885KMT2A 2469/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | ALDH1A1 4150/4885HSD17B10 1211/4885KMT2A 3292/4885 |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | ACVR1, TGFBR1, ACVRL1 | ALDH1A1 455/4885HSD17B10 2014/4885KMT2A 2474/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885HSD17B10 1470/4885KMT2A 1951/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | ALDH1A1 4276/4885HSD17B10 4064/4885KMT2A 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.